Results 241 to 250 of about 421,652 (362)

Impact of Maternal Diabetes on the Incidence of Critical Congenital Heart Disease in the United States. [PDF]

JACC Adv
Gonuguntla K, Abugrin M, Thyagaturu H, Younas HMW, Valand H, Upreti P, Patel HA, Chobufo MD, Sekar V, Shaik A, Khan MZ, Sattar Y, Gulati M.   +12 more
europepmc   +1 more source

Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration

European Journal of Heart Failure, EarlyView.
Deep phenotyping of of heart failure with preserved ejection fraction (HFpEF) through multi‐omics integration. AI, artificial intelligence. Aims Heart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality.
Jakob Versnjak, Titus Kuehne, Pauline Fahjen, Nina Jovanovic, Ulrike Löber, Gabriele G. Schiattarella, Nicola Wilck, Holger Gerhardt, Dominik N. Müller, Frank Edelmann, Philipp Mertins, Roland Eils, Michael Gotthardt, Sofia K. Forslund, Benjamin Wild, Marcus Kelm   +15 more
wiley   +1 more source

The Mayo Adult Congenital Heart Disease (MACHD) Registry and Biobank. [PDF]

JACC Adv
Egbe AC, Miranda WR, Connolly HM.
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Genetic and Environmental Contributors To Congenital Heart Disease. [PDF]

Curr Treat Options Cardiovasc Med
Choudhury TZ, Gilbert BL, Garg V.
europepmc   +1 more source

Critical Evaluation of Methods for the Identification of Aneugens

Environmental and Molecular Mutagenesis, EarlyView.
ABSTRACT The genotoxic potential of chemicals must be evaluated in regulatory safety assessment settings, including but not limited to, the development of new pharmaceuticals, industrial chemicals, food and cosmetic ingredients, and agrochemicals. Initial assessment of the chromosome‐damaging potential of chemicals is often conducted in mammalian cells
Xiaowen Sun, Stephen D. Dertinger, Azeddine Elhajouji, Daniel J. Roberts, Jan van Benthem, Maik Schuler, Shambhu Roy, Alexandra Taraboletti, Connie L. Chen   +8 more
wiley   +1 more source

Congenital Heart Disease with Congenital Malformation of the External Ear

, 1911
F. Parkes Weber
openalex   +1 more source

Cirrhosis of Liver Simulating Congenital Cyanotic Heart Disease [PDF]

, 1966
R. C. Hansoti, Nemish Shah
openalex   +1 more source

Utility of the joint index in newborn congenital heart disease screening. [PDF]

Sci Rep
Li M, He D, Peng T, Liu R, Tang B.
europepmc   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source